Therapeutic Challenges of Hepatic Mucormycosis in Hematologic Malignancy: A Case Report and Review of the Literature

Raffaele M. Bernardo, Ananta Gurung, Dhanpat Jain, Maricar F. Malinis

Corresponding Author: Raffaele M. Bernardo, e-mail: raffaele.bernardo@yale.edu

Conflict of interest: None declared

Patient: Female, 58
Final Diagnosis: Hepatic mucormycosis
Symptoms: Abdominal pain • fever
Medication: Amphotericin • posaconazole
Clinical Procedure: IR-guided aspiration
Specialty: Infectious Diseases

Objective: Rare disease
Background: The clinical presentation of mucormycosis can vary widely based on various host factors. Among malignancy- and bone marrow transplant-associated infections, the lungs are the most common site of infection. Involvement of the gastrointestinal tract is less frequently encountered. The clinical presentation is often nonspecific, and cultures typically yield no growth, making the diagnosis challenging.

Case Report: We present a case of isolated hepatic mucormycosis in the setting of neutropenic fever and abdominal pain following induction chemotherapy for the treatment of acute myeloid leukemia. The patient was treated with combination antifungal therapy with amphotericin and posaconazole without surgical resection, given the presence of multiple liver lesions. After a prolonged course of dual antifungal therapy, the size of her liver lesions improved. Unfortunately, her lymphoproliferative disorder proved fatal, following approximately 13 months of antifungal therapy.

Conclusions: Among patients with mucormycosis, mortality remains high, especially in the setting of gastrointestinal involvement. Although surgical resection along with dual antifungal therapy can improve outcomes, the high mortality rate necessitates further investigation into improved diagnostic and treatment strategies including optimal antifungal therapy.

MeSH Keywords: Amphotericin B • Antifungal Agents • Leukemia, Myeloid, Acute • Liver Abscess • Mucorales • Mucormycosis

Full-text PDF: http://www.amjcaserep.com/abstract/index/idArt/898480

This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
Background

The initial presentation of mucormycosis varies widely based on various host factors [1]. Although infection can be seen in patients with a relatively intact immune system, malignancy, especially hematologic malignancy, poses a particular risk for infection [1]. Pulmonary infections comprise more than 50% of all cases of malignancy- and bone marrow transplant-associated infections, whereas gastrointestinal tract infections comprise a much smaller percentage [1]. Isolated hepatic mucormycosis is an even less frequently encountered entity. Presentation is often nonspecific; however, patients with liver involvement frequently present with abdominal tenderness and liver function abnormalities [2]. Often, negative culture results further confound the diagnosis. We present a case of isolated hepatic mucormycosis in a woman following induction chemotherapy for the treatment of acute myeloid leukemia (AML) whose liver lesions improved following several months of dual antifungal therapy.

Case Report

A 58-year-old woman with AML was admitted to our hospital for evaluation of persistent hepatic abscesses despite broad-spectrum antibiotics. Upon presentation, she felt well and denied fever, anorexia, abdominal pain, nausea, or vomiting. She had been earlier diagnosed with a myelodysplastic syndrome, underwent chemotherapy with azacitadine, and was maintained on prophylaxis with moxifloxacin, valacyclovir, and voriconazole. Despite two cycles of chemotherapy, disease progressed to AML. Induction chemotherapy was initiated with idarubicin and cytarabine. Her course, however, was complicated by an idarubicin-associated cardiomyopathy and neutropenic fever.

One week following completion of her induction chemotherapy, the patient developed neutropenic fever and abdominal tenderness. A computed tomography (CT) scan of the abdomen was performed, demonstrating neutropenic enterocolitis. Additionally, a 2.8-cm subcapsular hepatic cyst and several additional hepatic hypodensities were noted. Because of persistent fever, she underwent a noncontrast CT scan of the chest 4 days later that revealed 3 new hypodense lesions within the liver (2.2 cm in the right lobe, 1.7 cm within the lateral segment of the left lobe, and 1.3 cm at the dome of the liver) that were not appreciated on earlier CT (Figure 1). A dedicated contrast CT of the abdomen revealed at least 9 new low-attenuation lesions throughout the liver including 1 measuring 2.6 cm with a halo of enhancement (Figure 2A, 2B).

After a failed attempt at a technically difficult aspiration by interventional radiology (IR) and resolution of her neutropenia, she was discharged home on levofloxacin and metronidazole with the presumptive diagnosis of bacterial hepatic abscesses. Several weeks following her discharge, she underwent follow-up CT imaging, again demonstrating multiple lesions throughout the liver, most with interval enlargement. A positron emission tomography (PET) CT scan found several of these lesions to be hypermetabolic, some with central necrosis (Figures 3A, 3B).

A liver biopsy performed 1 week following her PET CT scan revealed extensively infarcted liver parenchyma with numerous fungal hyphae (Figures 4, 5). The hyphae, which were highlighted with Periodic acid-Schiff (Figure 4) and Grocott (Figure 5) stains, appeared broad with occasional septa and branching (both acute and right angle) and raised a differential diagnosis of aspergillosis versus mucormycosis. Immunochemical testing using antibodies against Aspergillus and Mucor confirmed the fungus to represent Mucor. Because no growth was observed on culture, susceptibility testing could not be performed. Amphotericin B was started at 5 mg/kg every 24 hours.

Following approximately 10 days of therapy, her course was complicated by amphotericin-related nephrotoxicity. The amphotericin B dose was reduced to 3 mg/kg, and posaconazole was added. Despite 4 weeks of combination therapy and therapeutic posaconazole levels, hepatic lesions remained unchanged on PET CT scan. She underwent IR-guided drainage of the biggest lesion measuring 2.7 cm and placement of a catheter with subsequent drainage. The aspirate demonstrated an acute inflammatory exudate with fungal forms consistent with mucormycosis. Hepatectomy was considered; however, given the presence of multiple lesions, the decision was made to proceed with medical management.

After 2 months of dual antifungal therapy, the patient developed diarrhea, which was presumed to be posaconazole related. Her therapy was switched to anidulafungin and amphotericin with resolution of her diarrhea. Unfortunately, pancytopenia...
developed in the setting of AML progression, complicated by neutropenic fever and *Escherichia coli* bacteremia, which was treated with 14 days of ciprofloxacin. She was readmitted and underwent treatment with high-dose cytarabine, complicated by neutropenic fever and viridans group *Streptococcus* and *Klebsiella* bacteremia. In addition to her antifungal therapy...
for hepatic mucormycosis, she was discharged with levofloxacin for bacteremia. A follow-up PET CT scan almost 10 months after her initial presentation demonstrated improvement in her liver lesions; however, in addition to a new large pericardial effusion, multiple new areas of airspace disease were noted bilaterally, some with cavitation, as well as an intense focus of increased uptake in the left femur. None of her lung lesions were safely amenable to biopsy. She underwent pericardiocentesis with removal of 250 mL of serosanguinous material; pathologic evaluation was consistent with involvement of a hematolymphoid malignancy. Her course was further complicated by recurrent neutropenic fever, occult gastrointestinal bleed, and persistent thrombocytopenia. Given her grim prognosis, approximately 14 months following the initial identification of liver abscesses, the patient elected for comfort care measures and expired shortly thereafter.

**Discussion**

Mucormycosis is caused by a group of filamentous fungi that can affect many individuals, from the most heavily immunosuppressed to those with apparently intact immune systems. The more common organisms include species of *Rhizopus, Mucor, Cunninghamella, Apophysomyces*, and *Absidia* [1,3]. Pulmonary mucormycosis comprises the vast majority of infections among patients with underlying malignancy as well as those who underwent bone marrow or solid organ transplantation [1,4]. The gastrointestinal tract is involved in fewer than 10% of these patients, and hepatic involvement is rare [1]. It has been postulated that fungal hepatic abscesses are secondary to translocation of organisms from the colonized gut following mucosal breakdown [5]. One reported case suggested that ingestion of naturopathic medicine could be linked to hepatic mucormycosis [6].

Although several other cases of isolated hepatic mucormycosis have been described [2,6–13], to the best of our knowledge, this is the fourth reported case of hepatic mucormycosis in the setting of leukemia (Table 1). The common clinical presentation of all four cases was abdominal pain and fever. Multiple hepatic lesions were found on radiographic imaging in two cases, while the remaining cases had a single lesion. Diagnosis in this cohort was achieved by histopathology in three of the four cases.

**Table 1.** Reported cases of isolated hepatic mucormycosis with an underlying hematologic malignancy.

| Patient | Age/Sex | Leukemia | Presentation | Number of hepatic lesions | Diagnostic method | Treatment | Follow-up days | Status at last follow-up day | Reference |
|---------|---------|----------|--------------|---------------------------|-------------------|-----------|----------------|-------------------------------|-----------|
| 1       | 58/M    | AML      | LUQ pain, fever, and nausea | One (5 cm) | Culture | LamB + micafungin Percutaneous drainage but eventually required surgical resection | 60 days | Deceased due to Klebsiella pneumoniae and methicillin-resistant *Staphylococcus aureus* sepsis 60 days after resection | [2] |
| 2       | 21/M    | ALL      | Neutropenic fever and failure to thrive | Multiple (small, not measured) | Histopathology | AmB | Surgical resection | ~2 months | Alive | [11] |
| 3       | 9/M     | ALL      | Neutropenic fever and RUQ pain | One (4 cm) | Histopathology | LamB + posaconazole | Surgical resection | 2 years and 6 months | Alive | [12] |
| 4       | 58/F    | AML      | Neutropenic fever and abdominal pain | Nine (1.3–2.6 cm) | Histopathology | AmB then AmB + posaconazole; switched to AmB + anidulafungin | Percutaneous drainage | 14 months | Deceased likely from progression of malignancy | Current case |

M – male; F – female; ALL – acute lymphoblastic leukemia; AML – acute myeloid leukemia; LUQ – left upper quadrant; RUQ – right upper quadrant; LamB – liposomal amphotericin B; AmB – amphotericin B deoxycholate.

Bernardo R.M. et al.: Hepatic mucormycosis in patient with AML © Am J Case Rep, 2016; 17: 484-489
The Mucorales are typically difficult to grow in culture. The diagnosis is more often made by identification of the organism in histopathology by observing wide, thin-walled, and occasionally fragmented hyphae that contain few if any septae along with right-angle branching [14]. Immunohistochemical testing may have an advantage when distinguishing between aspergillosis and mucormycosis cannot be done morphologically [15]. Molecular diagnostic techniques, such as polymerase chain reaction, may provide a more rapid and sensitive result that can impact treatment decision [16,17], however, such assays will require further standardization and validation.

As mucormycosis becomes increasingly recognized among those with hematological malignancies with or without bone marrow transplantation, the approach and treatment of disease will need to be studied further. Mortality remains high, approaching 85% among those with gastrointestinal involvement [1]. Among patients with leukemia (Table 1), all-cause mortality is estimated to be 50%, despite therapy. Treatment often requires a combined medical and surgical approach. In one review, 532 patient received amphotericin B deoxylate with a 61% survival rate. Those who received both a surgical and medical approach had a 70% survival rate [1]. In addition to this approach, it has been suggested that dual antifungal therapy can also improve outcomes, typically utilizing a polyene as a backbone [18,19]. In one retrospective review of 41 cases of biopsy-proven rhino-orbital-cerebral mucormycosis, for example, outcomes of patients treated with polyene-casparofungin therapy plus surgical debridement were compared with those of patients who did not receive combination therapy. A 100% success rate was reported for all evaluable patients (n=6) at 30 days after hospital discharge, compared with 45% (n=45) with polyene monotherapy [20]. Successful treatment of rhino-cerebral mucormycosis with a combined approach utilizing surgical debridement and medical therapy with a polyene followed by posaconazole was previously reported [21]. Although surgical resection was not feasible in our patient, the use of dual antifungal therapy alone resulted in improvement of hepatic lesions, suggesting a role for this approach. Unfortunately, because none of her lung lesions were amenable to biopsy, it remains unclear whether these represented further Mucor dissemination or progression of her underlying lymphoproliferative disorder.

A new potential option for the treatment of invasive mold infections, including those secondary to Mucor species, is Isavuconazole, a second-generation triazole antifungal with high oral bioavailability [22]; however, further investigation is needed, including its role and efficacy used alone or in combination with amphotericin.

Conclusions

Outcomes for invasive mucormycosis remain poor, especially in the setting of hematologic malignancy. Although early diagnosis and aggressive treatment that includes surgery whenever possible may potentially improve outcomes, optimal treatment strategies have not yet been defined. With the development of newer and safer antifungal agents, combination antifungal therapy will likely remain fundamental to any treatment approach; however, further investigation into this area is needed.

References:

1. Roden MM, Zaoutis TE, Buchanan WL et al: Epidemiology and outcome of mucormycosis: A review of 929 reported cases. Clin Infect Dis, 2005; 41(5): 634–53
2. Su H, Thompson GR, III, Cohen SH: Hepatic mucormycosis with abscess formation. Diagn Microbiol Infect Dis, 2012; 73(2): 192–94
3. Pagano L, Cornely OA, Busca A et al: Combined antifungal approach for the treatment of invasive mucormycosis in patients with hematologic diseases: A report from the SEIFEM and FUNGISCOPe registries. Haematologica, 2013; 98(10): e127–30
4. Siwek GT, Dodgson KJ, de Magalhaes-Silverman M et al: Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis, 2004; 39(4): 584–87
5. Chasan R, Patel G, Malone A et al: Primary hepatic aspergillosis following induction chemotherapy for acute leukemia. Transpl Infect Dis, 2013; 15(5): E201–5
6. Oliver MR, Van Voorhis WC, Boeck M et al: Hepatic mucormycosis in a bone marrow transplant recipient who ingested naturopathic medicine. Clin Infect Dis, 1996; 22(3): 521–24
7. Khan AA, Kumaran V, Jain D et al: Hepatic mucormycosis in a patient of acute lymphoblastic leukemia: A case report with literature review. Indian J Hematol Blood Transfus, 2013; 29(2): 96–98
8. Tuyuzg S, Ozdemir N, Sener Y et al: Successful management of hepatic mucormycosis in an acute lymphoblastic leukaemia patient: A case report and review of the literature. Mycoses, 2014; 57(5): 513–18
9. Al-Asiri RH, Van Dijken PI, Mahmood MA et al: Isolated hepatic mucormycosis in an immunocompetent child. Am J Gastroenterol, 1996; 91(3): 606–7
10. Erdem G, Caglar M, Ceyhan M et al: Hepatic mucormycosis in a child with fulminant hepatic failure. Turk J Pediatr, 1996; 38(4): 511–14
11. Marco del Pont J, De Cicco L, Gallo G et al: Hepatic arterial thrombosis due to Mucor species in a child following orthotopic liver transplantation. Transpl Infect Dis, 2000; 2(1): 33–35
12. Mekoel KL, Hemming AW, Reed AI et al: Hepatic mucormycosis in a renal transplant recipient. Transplantation, 2005; 79(11): 1636
13. Abboud CS, Bergamasco MD, Baia CE et al: Case report of hepatic mucormycosis after liver transplantation: successful treatment with liposomal amphotericin B followed by posaconazole sequential therapy. Transplant Proc, 2012; 44(8): 2501–2
14. Guarnier J, Brandt ME: Histopathologic diagnosis of fungal infections in the 21st century. Clin Microbiol Rev, 2011; 24(2): 247–80
15. Jung J, Park YS, Sung H et al: Using immunohistochemistry to assess the accuracy of histomorphologic diagnosis of aspergillosis and mucormycosis. Clin Infect Dis, 2015; 61(11): 1664–70
16. Hammond SP, Bialek R, Milner DA et al: Molecular methods to improve diagnosis and identification of mucormycosis. J Clin Microbiol, 2011; 49(6): 2151–53
17. Walsh TJ, Gamaletou MN, McGinnis MR et al: Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis). Clin Infect Dis, 2012; 54(Suppl. 1): S55–60
18. Spellberg B, Ibrahim A, Roilides E et al: Combination therapy for mucormycosis: why, what, and how? Clin Infect Dis, 2012; 54(Suppl. 1): S73–78
19. Walsh TJ, Kontoyiannis DP: Editorial commentary: What is the role of combination therapy in management of zygomycosis? Clin Infect Dis, 2008; 47(3): 372–74
20. Reed C, Bryant R, Ibrahim AS et al: Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis, 2008; 47(3): 364–71
21. Lin SY, Lu PL, Tsai KB et al: A mucormycosis case in a cirrhotic patient successfully treated with posaconazole and review of published literature. Mycopathologia, 2012; 174(5–6): 499–504
22. Pettit NN, Carver PL: Isavuconazole: A new option for the management of invasive fungal infections. Ann Pharmacother, 2015; 49(7): 825–42